Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shuli Li

Showing results (221-230 of 233) with videos related to

Pageof 24
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2023
Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid LeukemiaAmir T Fathi, Haesook T Kim, Robert J Soiffer, et al.
JCO Precision Oncology|August 8, 2022
Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-BPhilippe L Bedard, Shuli Li, Kari B Wisinski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2020
Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)Keith T Flaherty, Robert J Gray, Alice P Chen, et al.
Blood|March 18, 2018
Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host diseaseMyrna R Nahas, Robert J Soiffer, Haesook T Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2019
Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) StudyNilofer S Azad, Robert J Gray, Michael J Overman, et al.
JCO Precision Oncology|April 13, 2023
Trametinib in Patients With <i>NF1-</i>, <i>GNAQ-</i>, or <i>GNA11</i>-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2Kari B Wisinski, Yael Flamand, Melissa A Wilson, et al.
Clinical and Translational Medicine|June 6, 2022
A pilot study of assessing whole genome sequencing in newborn screening in unselected children in ChinaMin Jian, Xiaohong Wang, Yuanyuan Sui, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 27, 2021
Differential Outcomes in Codon 12/13 and Codon 61 <i>NRAS</i>-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with <i>NRAS</i>-Mutated TumorsJames M Cleary, Victoria Wang, Rebecca S Heist, et al.
Nature Medicine|June 15, 2023
The NCI-MATCH trial: lessons for precision oncologyPeter J O'Dwyer, Robert J Gray, Keith T Flaherty, et al.
Stem Cells (Dayton, Ohio)|February 21, 2019
Coordinating Tissue Regeneration Through Transforming Growth Factor-β Activated Kinase 1 Inactivation and ReactivationHsiao Hsin Sung Hsieh, Shailesh Agarwal, David J Cholok, et al.
Pageof 24

Showing results (221-230 of 233) with videos related to

Sort By:
Pageof 24
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2023
Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid LeukemiaAmir T Fathi, Haesook T Kim, Robert J Soiffer, et al.
JCO Precision Oncology|August 8, 2022
Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-BPhilippe L Bedard, Shuli Li, Kari B Wisinski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2020
Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)Keith T Flaherty, Robert J Gray, Alice P Chen, et al.
Blood|March 18, 2018
Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host diseaseMyrna R Nahas, Robert J Soiffer, Haesook T Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2019
Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) StudyNilofer S Azad, Robert J Gray, Michael J Overman, et al.
JCO Precision Oncology|April 13, 2023
Trametinib in Patients With <i>NF1-</i>, <i>GNAQ-</i>, or <i>GNA11</i>-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2Kari B Wisinski, Yael Flamand, Melissa A Wilson, et al.
Clinical and Translational Medicine|June 6, 2022
A pilot study of assessing whole genome sequencing in newborn screening in unselected children in ChinaMin Jian, Xiaohong Wang, Yuanyuan Sui, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 27, 2021
Differential Outcomes in Codon 12/13 and Codon 61 <i>NRAS</i>-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with <i>NRAS</i>-Mutated TumorsJames M Cleary, Victoria Wang, Rebecca S Heist, et al.
Nature Medicine|June 15, 2023
The NCI-MATCH trial: lessons for precision oncologyPeter J O'Dwyer, Robert J Gray, Keith T Flaherty, et al.
Stem Cells (Dayton, Ohio)|February 21, 2019
Coordinating Tissue Regeneration Through Transforming Growth Factor-β Activated Kinase 1 Inactivation and ReactivationHsiao Hsin Sung Hsieh, Shailesh Agarwal, David J Cholok, et al.
Pageof 24